6 February 2017



ASX Announcement

Release of shares from escrow and expiry of options

Melbourne, Australia; 6 February 2017: Mach7 Technologies Limited (the **Company**) (ASX:**M7T**) advises in accordance with ASX Listing Rule 3.10A that 5,874,817 ordinary shares in the Company (**Shares**) will be released from escrow on 18 February 2017.

The Shares were issued in connection with the Company's acquisition of 3D Medical in 2015 (**Acquisition**), and are subject to ASX escrow restrictions for two years up until 18 February 2017. The Company will seek quotation of the Shares on the ASX upon their release from escrow on 18 February 2017.

The Company further confirms that 4,289,245 unlisted options (each exercisable at \$0.50), which were issued in connection with the Acquisition, will lapse today, 6 February 2017.

- ENDS

Contacts:

Jenni Pilcher	Alyn Tai
CEO Australia, CFO	Company Secretary
+61 3 9646 2222 (Australia)	+61 3 9286 7500 (Australia)
jenni.pilcher@mach7t.com	alyn.tai@mach7t.com

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) develops innovative enterprise imaging IT solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7's award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7's sophisticated workflow tools, advanced <u>clinical viewing</u> and optimised <u>vendor neutral archiving</u> solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit <u>www.mach7t.com</u>

Mach7's wholly-owned subsidiary, 3D Medical Pty Ltd, provides medical specific 3D printing and is an exclusive distributor of various synergistic technologies including holographic projection. 3D Medical's innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes. Visit <u>www.3dmedical.com.au</u>